Author:
Kam Grace,Yiu Richard,Loh Yvonne,Ang Ai Leen,Yueh Ling Ling,Goh Yeow Tee,Wong Gee Chuan
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA et al (2013) Acute myeloid leukemia, version 2.2013. J Natl Compr Cancer Netw 11(9):1047–1055
2. Klastersky J (2004) Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39(Suppl 1):S32–S37
3. Harousseau JL, Witz B, Lioure B, Hunault-Berger M, Desablens B, Delain M et al (2000) Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 18(4):780–787
4. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G et al (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Int Acute Myeloid Leuk Study Group Blood 90(12):4710–4718
5. Bradley AM, Deal AM, Buie LW, Van DH (2012) Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor. Pharmacotherapy 32(12):1070–1077. doi: 10.1002/phar.1150